@KalaGhazi Esperion Therapeutics Big drop yesterday. Will it rally or back down again???
Target price is 11 $ That's enough:) If u have any questions make a comment below
In February 2020, both Nexletol and Nexlizet were approved as oral treatments to lower LDL-C. Bempedoic acid remains in clinical trials of its efficacy in risk reduction for cardiovascular disease. Esperion shares peaked last February, after the FDA approvals, but since then, the stock has declined. Shares are down 65% since their peak. (tipranks.com) Analyst...
Looking at weekly chart we can observe ESPR history, that can be summarized in 2 double tops and a rising channel. At the moment we have broken out the channel to the upside, gaining about 30% during the past weeks. A significant level for this stock could be the 20$ area, that is the higher hight and it wasn't touched from August 2013. If you have a look to...